Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sironax Closes $200 Million Round for Novel Degenerative Disease Therapies

publication date: Aug 2, 2022

Beijing Sironax closed a $200 million Series B financing to advance its portfolio of novel therapies for age-related degenerative diseases. The company’s pipeline consists of products that address key mechanisms underlying age-related degenerative diseases --regulated cell death, neuroprotective pathways and neuroinflammation. Its lead candidate is a serine/threonine-protein kinase 1 (RIPK1) inhibitor that has started clinical trials for COVID and an unspecified degenerative disease. The B round was led by Gaorong Capital and Yunfeng Capital. Sironax has now raised $300 million. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital